The majority of NSCLC patients are diagnosed with advanced-stage disease which is concomitant with an exceptionally poor prognosis, 5-year survival rate of 4%. In contrast, tumors detected at an early stage have 5-year survival rates of 54%. …
The research is published online October 16, 2014 in the journal Cancer Cell. Molecules associated with these cells, newly identified by the UCSF researchers, could be the focus of new immunotherapies that are more precisely targeted than current immunotherapies now in clinical trials, said Matthew Krummel, PhD, professor of pathology at UCSF and the leader of the study. In fact, the UCSF researchers concluded that the presence of these cells may be the reason current immunotherapies aimed at boosting T lymphocyte responses have any effectiveness whatsoever. Krummel’s lab team depleted the population of these already rare cells in mice and demonstrated that the immune system was then unable to control tumors, even when the mice were given immunotherapeutic treatments…
Researchers at Duke Medicine have found a way to kill prostate cancer cells by delivering a trove of copper along with a drug that selectively destroys the diseased cells brimming with the mineral, leaving non-cancer cells healthy. The combination approach, which uses two drugs already commercially available for other uses, could soon be tested in clinical trials among patients with late-stage disease. …
Researchers at Duke Medicine have found a way to kill prostate cancer cells by delivering a trove of copper along with a drug that selectively destroys the diseased cells brimming with the mineral, leaving non-cancer cells healthy. The combination approach, which uses two drugs already commercially available for other uses, could soon be tested in clinical trials among patients with late-stage disease. “This proclivity for copper uptake is something we have known could be an Achilles’ heel in prostate cancer tumors as well as other cancers,” said Donald McDonnell, Ph.D., chairman of the Duke Department of Pharmacology and Cancer Biology and senior author of a study published Oct. …
“While laboratory studies support an important role for cholesterol in prostate cancer, population-based evidence linking cholesterol and prostate cancer is mixed,” said Emma Allott, PhD, postdoctoral associate at Duke University School of Medicine in Durham, North Carolina. “Understanding associations between obesity, cholesterol, and prostate cancer is important given that cholesterol levels are readily modifiable with diet and/or statin use, and could therefore have important, practical implications for prostate cancer prevention and treatment. “Our findings suggest that normalization, or even partial normalization, of serum lipid levels among men with dyslipidemia [abnormal lipid profile] may reduce the risk of prostate cancer recurrence,” said Allott. Allott, Stephen Freedland, MD, associate professor of surgery at Duke University School of Medicine, and colleagues, analyzed data from 843 men who underwent radical prostatectomy after a prostate cancer diagnosis and who never took statins before surgery. …
The results reported in the journal of Clinical Cancer Research, a publication of the American Association of Cancer Research, indicate the KLK3 gene — a gene on chromosome 19 responsible for encoding the prostate-specific antigen (PSA) — is not only associated with prostate cancer aggression, but a single nucleotide polymorphism (SNP) on it is more apparent in cancer patients with GS7. Researchers have linked Gleason score, an important predictor of prostate cancer outcomes, to several clinical end points, including clinical stage, cancer aggression and survival. …
The results reported in the journal of Clinical Cancer Research, a publication of the American Association of Cancer Research, indicate the KLK3 gene — a gene on chromosome 19 responsible for encoding the prostate-specific antigen (PSA) — is not only associated with prostate cancer aggression, but a single nucleotide polymorphism (SNP) on it is more apparent in cancer patients with GS7. Researchers have linked Gleason score, an important predictor of prostate cancer outcomes, to several clinical end points, including clinical stage, cancer aggression and survival. There has been much research associated with prostate cancer outcomes as well as GS7 prostate cancers, which is an intermediate grade of cancer accounting for 30 to 40 percent of all prostate cancers. “This is the first report that I am aware of that indicates a genetic variant can stratify GS7 prostate cancer patients,” said Jian Gu, Ph.D., associate professor at MD Anderson, and a key investigator on the study. …
“Our study shows that a high percentage of follow-up colonoscopies are being performed too early, resulting in use of scarce health care resources with potentially limited clinical benefit,” said Thomas D. Sequist MD, MPH, BWH Division of General Medicine and Primary Care, senior study author…
Led by Associate Professor Chng Wee Joo, Deputy Director and Senior Principal Investigator at CSI Singapore and Director of the National University Cancer Institute, Singapore, the scientists discovered that inhibition of Leo1 and Leo1 downstream signalling pathways provide an avenue for targeted treatment of AML. The findings were recently published in Cancer Research, the official journal of the American Association of Cancer Research. …
Researchers from Boston University’s Slone Epidemiology Center (SEC) collaborated with the Roswell Park Cancer Institute of Buffalo, NY and the University of North Carolina Lineberger Cancer Center to form a consortium to study the determinants of breast cancer subtypes in African American women. They combined data on breast cancer cases and controls from four large studies, including the Boston University Black Women’s Health Study…